economy
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
TL;DR
- Approximately 1 in 8 American adults are taking GLP-1 drugs, popular for weight loss.
- These drugs slow digestion, suppress appetite, and increase satiety, leading users to consume fewer calories and spend less on food.
- JPMorgan estimates GLP-1 drug use could reduce food and beverage industry sales by $30-$55 billion annually by 2030.
- The restaurant industry is seeing impacts on snacking, breakfast, and dinner sales, with some users dining out less frequently.
- Food and beverage companies are adapting by launching protein- and fiber-rich products, smaller portion sizes, and marketing explicitly to GLP-1 users.
- The shift to pill versions of GLP-1 medications is expected to further increase adoption rates.
- Some consumers may cycle on and off GLP-1 medications, creating a dynamic consumer behavior for manufacturers to consider.